Precision BioSciences (DTIL) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Protara Therapeutics (TARA) over the past year, gaining 12.8% versus a loss of 47.7%. Over five years, TARA leads with a -61.3% price change compared with -97.8% for DTIL. Precision BioSciences is the larger company by market cap ($187.8 million vs $160.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | TARA |
|---|---|---|
| Share price | $6.81 | $2.72 |
| Market cap | $187.83M | $160.74M |
| 1-day change | +5.83% | +2.64% |
| YTD return | +54.57% | -50.28% |
| 1-year return | +12.81% | -47.73% |
| 5-year return | -97.81% | -61.26% |
| EPS (TTM) | $-1.35 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.62 | $7.82 |
| 52-week low | $3.53 | $2.51 |
| Distance from 52-week high | -29.26% | -65.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +332.04% | +845.22% |
| Average volume | 287.13K | 814.80K |
| Shares outstanding | 27.60M | 59.10M |
| Employees | 67 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed TARA by 60.5 percentage points over the past year.
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
DTIL vs TARA FAQ
Which is bigger, Precision BioSciences or Protara Therapeutics?
Precision BioSciences (DTIL) is larger, with a market capitalization of $187.83M compared with $160.74M for Protara Therapeutics (TARA).
Which stock has performed better over the past year, DTIL or TARA?
DTIL returned +12.81% over the past 12 months, compared with -47.73% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Precision BioSciences and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.